- Home
- Publications
- Publication Search
- Publication Details
Title
Atezolizumab for the treatment of breast cancer
Authors
Keywords
-
Journal
EXPERT OPINION ON BIOLOGICAL THERAPY
Volume 18, Issue 5, Pages 595-603
Publisher
Informa UK Limited
Online
2018-04-25
DOI
10.1080/14712598.2018.1469619
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Tumour infiltrating lymphocytes in breast cancer: increasing clinical relevance
- (2018) Roberto Salgado et al. LANCET ONCOLOGY
- Tumour-infiltrating lymphocytes and prognosis in different subtypes of breast cancer: a pooled analysis of 3771 patients treated with neoadjuvant therapy
- (2018) Carsten Denkert et al. LANCET ONCOLOGY
- Immunotherapy for colorectal cancer: where are we heading?
- (2017) Debora Basile et al. EXPERT OPINION ON BIOLOGICAL THERAPY
- Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)
- (2017) Solange Peters et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial
- (2017) Achim Rittmeyer et al. LANCET
- Safety and Tolerability of PD‐1/PD‐L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta‐Analysis
- (2017) Tomohiro F. Nishijima et al. ONCOLOGIST
- Atezolizumab Extends Survival for Breast Cancer
- (2017) Cancer Discovery
- Atezolizumab for the treatment of non-small cell lung cancer
- (2017) Fernando C. Santini et al. Expert Review of Clinical Pharmacology
- Abstract S1-04: Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: A phase Ib JAVELIN solid tumor trial
- (2016) LY Dirix et al. CANCER RESEARCH
- Atezolizumab: A PD-L1–Blocking Antibody for Bladder Cancer
- (2016) Brant A. Inman et al. CLINICAL CANCER RESEARCH
- PD-L1 (B7-H1) expression and the immune tumor microenvironment in primary and metastatic breast carcinomas
- (2016) Ashley Cimino-Mathews et al. HUMAN PATHOLOGY
- Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma
- (2016) Antoni Ribas et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The impact of hypoxia on tumor-associated macrophages
- (2016) Anne-Theres Henze et al. JOURNAL OF CLINICAL INVESTIGATION
- Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study
- (2016) Rita Nanda et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
- (2016) Louis Fehrenbacher et al. LANCET
- Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
- (2016) Jonathan E Rosenberg et al. LANCET
- Standardized evaluation of tumor-infiltrating lymphocytes in breast cancer: results of the ring studies of the international immuno-oncology biomarker working group
- (2016) Carsten Denkert et al. MODERN PATHOLOGY
- The Role of the Tumor Vasculature in the Host Immune Response: Implications for Therapeutic Strategies Targeting the Tumor Microenvironment
- (2016) Shona A. Hendry et al. Frontiers in Immunology
- The Prognostic Value of Tumor-Infiltrating Lymphocytes in Breast Cancer: A Systematic Review and Meta-Analysis
- (2016) Yan Mao et al. PLoS One
- Abstract 2859: Inhibition of PD-L1 by MPDL3280A leads to clinical activity in patients with metastatic triple-negative breast cancer (TNBC)
- (2015) Leisha A. Emens et al. CANCER RESEARCH
- Prognostic and predictive value of tumor-infiltrating lymphocytes in breast cancer: a systematic review and meta-analysis
- (2015) X. Yu et al. Clinical & Translational Oncology
- RAS/MAPK Activation Is Associated with Reduced Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancer: Therapeutic Cooperation Between MEK and PD-1/PD-L1 Immune Checkpoint Inhibitors
- (2015) S. Loi et al. CLINICAL CANCER RESEARCH
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Clinical relevance of host immunity in breast cancer: from TILs to the clinic
- (2015) Peter Savas et al. Nature Reviews Clinical Oncology
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antagonists of PD-1 and PD-L1 in Cancer Treatment
- (2015) Evan J. Lipson et al. SEMINARS IN ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
- (2014) Ezzeldin M. Ibrahim et al. BREAST CANCER RESEARCH AND TREATMENT
- Clonal evolution in breast cancer revealed by single nucleus genome sequencing
- (2014) Yong Wang et al. NATURE
- Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients
- (2014) Roy S. Herbst et al. NATURE
- Tumour-infiltrating CD8+ lymphocytes as an independent predictive factor for pathological complete response to primary systemic therapy in breast cancer
- (2013) A N Seo et al. BRITISH JOURNAL OF CANCER
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating CD8+ Lymphocytes Predict Clinical Outcome in Breast Cancer
- (2011) Sahar M.A. Mahmoud et al. JOURNAL OF CLINICAL ONCOLOGY
- Integrated molecular profiles of invasive breast tumors and ductal carcinoma in situ (DCIS) reveal differential vascular and interleukin signaling
- (2011) V. N. Kristensen et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Improved prognostic classification of breast cancer defined by antagonistic activation patterns of immune response pathway modules
- (2010) Andrew E Teschendorff et al. BMC CANCER
- Macrophage plasticity and interaction with lymphocyte subsets: cancer as a paradigm
- (2010) Subhra K Biswas et al. NATURE IMMUNOLOGY
- Possible involvement of regulatory T cells in tumor onset and progression in primary breast cancer
- (2008) Masahiro Ohara et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationPublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More